Markets
Wood Blocks Stack Bar Graph
Getty Images
Remix

There are now more ETFs than stocks in the US, and many of them aren’t vanilla

From sin stocks to K-pop, pets to extraterrestrial life… there’s an ETF for everything now.

Claire Yubin Oh
9/1/25 9:28AM

According to Morningstar data first reported by Bloomberg last week, there are now some 4,400 exchange-traded funds listed in the US, surpassing the number of American public companies.

Remix market

Typically offering a tax efficient, flexible, and easy-to-access vehicle for investing, the ETF market has exploded, with more than 640 new ETFs launched this year — equivalent to about four per day — as investors have piled over $660 billion into the ETF market in the first seven months of this year. 

There are more etfs than stocks
Sherwood News

As Tker.co’s Sam Ro comments, it’s like having more recipes than there are ingredients — just like how chicken can go great in a sandwich, or a roast dinner, or a spicy curry, now major stocks routinely find themselves in hundreds of ETFs. Apple, for example, is in a bunch of tech ETFs, US-based ETFs, dividend ETFs, and megacap ETFs, to name but a few.

The trailblazers of the ETF world, passive low-cost index-tracking funds like VOO or SPY, are still the biggest in the game. But what’s changed in recent years is that the recipes have been getting spicier.

As of July this year, 37% of all new money in the ETF world flew into active ETFs, compared to only 3% in 2015. Rather than track a simple benchmark or theme, managers of these funds make investment decisions in the hope of finding better returns. They also tend to charge higher fees.

Many of these active ETF strategies follow classic investing styles like value, momentum, or income. Others are getting creative with derivatives, or niche categories, like the politically conservative YALL or the sin stocks fund VICE. Some of the biggest, like Cathie Wood’s innovation-heavy ARKK, have experienced serious boom and bust periods.

Once hailed as a simple way to invest with just a few options, now there’s an ETF for everything... if you have the patience to trawl through all 4,400 of them to find it.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.